ININFA   02677
INSTITUTO DE INVESTIGACIONES FARMACOLOGICAS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
- Omega-3 fatty acid potentiation of fluoxetine and mirtazapine antidepressant effects.
Autor/es:
LAINO, C., FONSECA C., STERIN-SPEZIALE N, REINÉS, A
Lugar:
Tandil
Reunión:
Congreso; Reunión Anual de la Sociedad Argentina de Farmacología Experimental (SAFE),; 2008
Institución organizadora:
Sociedad Argentina de Farmacología Experimental (SAFE),
Resumen:
Epidemiological studies indicate an association between depression and low dietary intake of omega-3 (ù-3) fatty acids. However, robust preclinical characterization of the ù-3 antidepressant effect is still lacking. The aim of this study was to examine in rats the antidepressant effects of ù-3 supplementation alone as well as in combined chronic treatments with antidepressants fluoxetine (FLX) or mirtazapine (MTZ) in the forced swimming test. We found that compared to control diet, ù-3 supplementation dose-dependently increased behaviors of swimming, indicative of the ù-3 antidepressant-like effect. Co-administration of FLX (1 or 10 mg/kg/day) or MTZ (20 mg/kg/day) and ù-3 fatty acids (0.72 g/kg/day) revealed higher antidepressant efficacy than the individual treatments. Biochemical studies showed that compared to control diet, ù-3 supplementation increased docosahexaenoic acid (DHA) levels in brain membranes without modifying the composition of phospholipid classes. It can be suggested that ù-3 may potentiate antidepressant drug actions possibly by increasing the DHA proportion in brain membrane phospholipids. ù-3) fatty acids. However, robust preclinical characterization of the ù-3 antidepressant effect is still lacking. The aim of this study was to examine in rats the antidepressant effects of ù-3 supplementation alone as well as in combined chronic treatments with antidepressants fluoxetine (FLX) or mirtazapine (MTZ) in the forced swimming test. We found that compared to control diet, ù-3 supplementation dose-dependently increased behaviors of swimming, indicative of the ù-3 antidepressant-like effect. Co-administration of FLX (1 or 10 mg/kg/day) or MTZ (20 mg/kg/day) and ù-3 fatty acids (0.72 g/kg/day) revealed higher antidepressant efficacy than the individual treatments. Biochemical studies showed that compared to control diet, ù-3 supplementation increased docosahexaenoic acid (DHA) levels in brain membranes without modifying the composition of phospholipid classes. It can be suggested that ù-3 may potentiate antidepressant drug actions possibly by increasing the DHA proportion in brain membrane phospholipids.